Oppenheimer upgrades BioMarin on long term outlook

Investing.com

02-24

Investing.com -- Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term financial outlook under new leadership. The firm set a new price target of $98 on BioMarin shares.

BioMarin posted fourth-quarter revenue of $747 million, exceeding the $712 million consensus estimate, and provided 2025 guidance with both revenue and earnings expectations above Street estimates.

Oppenheimer highlighted the continued global rollout of Voxzogo, which it believes has sizable untapped potential, and projected 2025 sales of $945 million.

The firm noted BioMarin’s focus on operational efficiency, cost reductions, and strategic R&D investments, as well as upcoming pipeline catalysts, including data readouts for BMN 351 and BMN 333 later this year.

Oppenheimer raised its revenue estimates through 2027 and expects BioMarin’s cost transformation program to yield full benefits by 2026.

Related Articles

Oppenheimer upgrades BioMarin on long term outlook

Amgen India opens with $200 million investment plan through 2025

National Grid sells $1.7 billion US renewables arm to Brookfield

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2513780267"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2513780267\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2513780267?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 23:24","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2513780267","market":"us","top_or_hot":-1,"title":"Oppenheimer upgrades BioMarin on long term outlook","media":"Investing.com","content":"<html><body><p>Investing.com -- Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to \"Outperform\" from \"Perform,\" citing strong fourth-quarter results and increasing confidence in the company's long-term financial outlook under new leadership. The firm set a new price target of $98 on BioMarin shares.</p>\n<p>BioMarin posted fourth-quarter revenue of $747 million, exceeding the $712 million consensus estimate, and provided 2025 guidance with both revenue and earnings expectations above Street estimates. <br/><br/>Oppenheimer highlighted the continued global rollout of Voxzogo, which it believes has sizable untapped potential, and projected 2025 sales of $945 million.</p>\n<p>The firm noted BioMarin’s focus on operational efficiency, cost reductions, and strategic R&amp;D investments, as well as upcoming pipeline catalysts, including data readouts for BMN 351 and BMN 333 later this year. <br/><br/>Oppenheimer raised its revenue estimates through 2027 and expects BioMarin’s cost transformation program to yield full benefits by 2026.</p>\n<p>Related Articles</p>\n<p>Oppenheimer upgrades BioMarin on long term outlook</p>\n<p>Amgen India opens with $200 million investment plan through 2025</p>\n<p>National Grid sells $1.7 billion US renewables arm to <a href=\"https://laohu8.com/S/BN\">Brookfield</a></p>\n</body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oppenheimer upgrades BioMarin on long term outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOppenheimer upgrades BioMarin on long term outlook\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2025-02-24 23:24</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>Investing.com -- Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to \"Outperform\" from \"Perform,\" citing strong fourth-quarter results and increasing confidence in the company's long-term financial outlook under new leadership. The firm set a new price target of $98 on BioMarin shares.</p>\n<p>BioMarin posted fourth-quarter revenue of $747 million, exceeding the $712 million consensus estimate, and provided 2025 guidance with both revenue and earnings expectations above Street estimates. <br/><br/>Oppenheimer highlighted the continued global rollout of Voxzogo, which it believes has sizable untapped potential, and projected 2025 sales of $945 million.</p>\n<p>The firm noted BioMarin’s focus on operational efficiency, cost reductions, and strategic R&amp;D investments, as well as upcoming pipeline catalysts, including data readouts for BMN 351 and BMN 333 later this year. <br/><br/>Oppenheimer raised its revenue estimates through 2027 and expects BioMarin’s cost transformation program to yield full benefits by 2026.</p>\n<p>Related Articles</p>\n<p>Oppenheimer upgrades BioMarin on long term outlook</p>\n<p>Amgen India opens with $200 million investment plan through 2025</p>\n<p>National Grid sells $1.7 billion US renewables arm to <a href=\"https://laohu8.com/S/BN\">Brookfield</a></p>\n</body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/oppenheimer-upgrades-biomarin-long-term-152402944.html\">Investing.com</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPY","symbol_name":"奧本海默控股","start_time":0,"source_url":"https://finance.yahoo.com/news/oppenheimer-upgrades-biomarin-long-term-152402944.html","article_id":"2513780267","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513780267","pubTimestamp":1740410642,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Investing.com --Oppenheimer upgraded Biomarin Pharmaceutical  Inc  to \"Outperform\" from \"Perform,\" citing strong fourth-quarter results and increasing confidence in the company's long-term financial outlook under new leadership. The firm set a new price target of $98 on BioMarin shares.BioMarin posted fourth-quarter revenue of $747 million, exceeding the $712 million consensus estimate, and provided 2025 guidance with both revenue and earnings expectations above Street estimates. Oppenheimer highlighted the continued global rollout of Voxzogo, which it believes has sizable untapped potential, and projected 2025 sales of $945 million.The firm noted BioMarin’s focus on operational efficiency, cost reductions, and strategic R&D investments, as well as upcoming pipeline catalysts, including data readouts for BMN 351 and BMN 333 later this year. Oppenheimer raised its revenue estimates through 2027 and expects BioMarin’s cost transformation program to yield full benefits by 2026.Amgen India","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"OPY":"奥本海默控股","BMRN":"拜玛林制药"},"translate_title":"奥本海默升级BioMarin的长期前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":0.9,"OPY":1},"content_text":"Investing.com -- Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to \"Outperform\" from \"Perform,\" citing strong fourth-quarter results and increasing confidence in the company's long-term financial outlook under new leadership. The firm set a new price target of $98 on BioMarin shares.\nBioMarin posted fourth-quarter revenue of $747 million, exceeding the $712 million consensus estimate, and provided 2025 guidance with both revenue and earnings expectations above Street estimates. Oppenheimer highlighted the continued global rollout of Voxzogo, which it believes has sizable untapped potential, and projected 2025 sales of $945 million.\nThe firm noted BioMarin’s focus on operational efficiency, cost reductions, and strategic R&D investments, as well as upcoming pipeline catalysts, including data readouts for BMN 351 and BMN 333 later this year. Oppenheimer raised its revenue estimates through 2027 and expects BioMarin’s cost transformation program to yield full benefits by 2026.\nRelated Articles\nOppenheimer upgrades BioMarin on long term outlook\nAmgen India opens with $200 million investment plan through 2025\nNational Grid sells $1.7 billion US renewables arm to Brookfield","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}